Medicare enrollees will save more than 50% on out-of-pocket costs for 10 common prescription drugs under their insurance ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Eli Lilly's oral pill helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

In topline results of the ATTAIN-MAINTAIN trial, people who lost weight with an injectable GLP-1 were able to keep weight off when switched to an oral GLP-1, Eli Lilly announced.For ATTAIN-MAINTAIN, ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

According to the study, orforglipron users maintained their weight loss levels more closely after previously taking a rival's ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

In the ATTAIN-MAINTAIN study of its orforglipron candidate, switching to the drug after 72 months of injectable treatment ...

Pop Mart, the Chinese firm behind the mischievously grinning, nine-toothed Labubu dolls that shoppers have queued up to buy ...

Popular new anti-obesity medications can help people lose 10% to 20% of their body weight, yet a new study indicates that about 40% of those prescriptions go unfilled. Affordability, say researchers, ...